What you should know:
1. To receive the approval, AbbVie sold its stake in brazikumab to AstraZeneca. Brazikumab is an IL-23 inhibitor for autoimmune diseases.
2. The commission issued its conditional approval for the acquisition in January, requiring AbbVie to find a pharmaceutical company to divest brazikumab to.
3. AbbVie can now close the pending transaction in Europe. The deal has to earn FTC approval and Irish High Court approval.
4. AbbVie believes the FTC will make a decision in the second quarter of 2020.
More articles on surgery centers:
3 ways to improve ASC revenue cycle performance
Indiana legislators meet resistance on price transparency bill
Maximizing reimbursements in ASCs: A review of reimbursement methodology
